Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025-February 2024-www.financetom.com

Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025

Nov 4, 2024 2:43 PM

Nov 4 (Reuters) - Telehealth firm Hims & Hers Health ( HIMS )

said on Monday it plans to bring a generic version of

Novo Nordisk's diabetes drug, Liraglutide, to its

platform in 2025.

Previous page： Eyeing 42-45% revenue growth in FY21, says ITI Next page： How YouTube decides what to ban

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Eyeing 42-45% revenue growth in FY21, says ITI

Jan 7, 2020

Optimistic on the business outlook going forward, the Chairman and Managing Director of ITI, RM Agarwal said revenue target for Q4 is much higher than Q3 because total MoU target with the government of India stand at Rs 3,500 crore.

How YouTube decides what to ban

Jan 6, 2020

The Google-owned site has come under fire recently for allowing videos that feature what many find offensive or violent, and for not doing enough to protect kids online.

Indian millennials fall in love with true smartwatches

Jan 5, 2020

The country saw the arrival of 1.87 lakh smartwatches in the third quarter, registering 28 percent QoQ growth and 93 percent YoY growth.

Apple can make 2020 its strongest year in India

Jan 5, 2020

Thrust on manufacturing high-end iPhones locally along with the first-ever flagship retail store would give Apple a booster in the price-sensitive smartphone market in 2020.